MLH1 deficiency suppresses glioblastoma growth and enhances αPD-1 efficacy via the cGAS/STING pathway
Glioblastoma (GBM) resistance to immune checkpoint inhibitors remains a major clinical challenge, largely due to its immunosuppressive tumor microenvironment. DNA mismatch repair protein MutL Homolog 1 (MLH1) participates in genome stability maintenance, yet its functional role and regulatory mechanism modulating GBM anti-tumor immunity remain poorly defined. Here we show MLH1 is overexpressed in GBM and correlates with immune regulation. Mechanistically, MLH1 associates with EXO1 and negatively regulates its protein expression. MLH1 knockdown relieves this suppression, which is accompanied by EXO1 accumulation, DNA damage, cGAS/STING pathway activation, and increased IFN- β production, all of which are reversed by the co-knockdown of MLH1 and EXO1. In orthotopic and subcutaneous syngeneic glioma models, MLH1 knockdown suppressed tumor growth and was accompanied by increased CD8 + cell infiltration and elevated expression of effector molecules. Furthermore, combining MLH1 knockdown with αPD-1 therapy exerted enhanced anti-tumor efficacy. Collectively, MLH1 deficiency activates the cGAS/STING pathway in association with EXO1, and enhances the efficacy of PD-1 blockade, which may provide a potential therapeutic strategy to overcome immunotherapy resistance in GBM.
Authors
- 周静铮
- Shuxin Song (ORCID: https://orcid.org/0000-0002-2039-118X)
- Bing Xiao (ORCID: https://orcid.org/0000-0001-6572-5641)
- Jianming Zhu (ORCID: https://orcid.org/0000-0002-4159-2191)
- Wei He
- Zhihua Chen
- Hongbing Wu
Institutions
- Second Affiliated Hospital of Nanchang University (CN)
Publication Details
- Journal
- Cancer Immunology Immunotherapy
- Published
- 2026-11-21
- DOI
- https://doi.org/10.1007/s00262-026-04651-1
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00